Literature DB >> 18301296

Faecal calprotectin: a noninvasive diagnostic tool and marker of severity in pouchitis.

Matt W Johnson1, Susan Maestranzi, Audrey M Duffy, David H Dewar, Alastair Forbes, Ingvar Bjarnason, Roy A Sherwood, Paul Ciclitira, John R Nicholls.   

Abstract

INTRODUCTION: In pouchitis, the mucosa is infiltrated by activated polymorphonuclear neutrophils capable of producing calprotectin, a stable antimicrobial myelomonocytic protein. AIM: The aim is to assess the ability of faecal calprotectin to differentiate between inflamed and noninflamed ileal pouches, and to correlate this with inflammation severity using the newly developed Objective Pouchitis Score.
METHOD: Fifty-four stool samples were collected from patients who had undergone restorative proctocolectomy; 46 from patients with ulcerative colitis and eight from those with familial adenomatous polyposis coli. Faecal calprotectin concentrations were determined by quantitative enzyme-linked immunosorbant assay.
RESULTS: Of the ulcerative colitis patients, six were diagnosed with pouchitis and pre-pouch ileitis (median faecal calprotectin: 865 microg/g, with a range of 95-2350 microg/g); 13 had pouchitis alone (145, 33-3350 microg/g) and 27 were uninflamed (56, 4-705 microg/g). Of the familial adenomatous polyposis patients, one had pouchitis and pre-pouch ileitis (305 microg/g), and seven had noninflamed pouches (9, 6-26 microg/g). Stool samples obtained from pouchitis patients had significantly higher calprotectin concentrations compared with those obtained from uninflamed pouches (Mann-Whitney: P<0.0001). Faecal calprotectin concentrations correlated closely with the Objective Pouchitis Score, the Pouch Disease Activity Index and endoscopic and histological inflammatory scores (Spearman rank test: P values <0.0001). Using a faecal calprotectin threshold of >or=92.5 microg/g to define a positive result, Receiver Operating Characteristic analysis demonstrated a sensitivity of 90% and a specificity of 76.5%.
CONCLUSION: Faecal calprotectin measurement is a useful noninvasive tool in the diagnosis of acutely inflamed ileal pouches and correlates well with the severity of pouchitis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18301296     DOI: 10.1097/MEG.0b013e3282f1c9a7

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  22 in total

Review 1.  Acute and chronic pouchitis--pathogenesis, diagnosis and treatment.

Authors:  Bo Shen
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2012-04-17       Impact factor: 46.802

2.  Utility of fecal and serum anti-Saccharomyces cerevisiae antibodies in the diagnosis of Crohn's disease-like condition of the pouch.

Authors:  Linda Y Tang; Hui Cai; Udayakumar Navaneethan; James H Boone; Sarah J Rhodes; Lauren Moore; Hyunjin Rho; Carol de La Motte; Elaine Queener; Bo Shen
Journal:  Int J Colorectal Dis       Date:  2012-03-20       Impact factor: 2.571

Review 3.  Diagnosis and management of pouchitis and ileoanal pouch dysfunction.

Authors:  Udayakumar Navaneethan; Bo Shen
Journal:  Curr Gastroenterol Rep       Date:  2010-12

Review 4.  The role and utility of faecal markers in inflammatory bowel disease.

Authors:  Frank S Lehmann; Emanuel Burri; Christoph Beglinger
Journal:  Therap Adv Gastroenterol       Date:  2015-01       Impact factor: 4.409

5.  The Use of Fecal Calprotectin in Inflammatory Bowel Disease.

Authors:  Ingvar Bjarnason
Journal:  Gastroenterol Hepatol (N Y)       Date:  2017-01

6.  Utility of faecal calprotectin analysis in adult inflammatory bowel disease.

Authors:  Lyn A Smith; Daniel R Gaya
Journal:  World J Gastroenterol       Date:  2012-12-14       Impact factor: 5.742

Review 7.  Calprotectin, calgranulin C, and other members of the s100 protein family in inflammatory bowel disease.

Authors:  Anastassios C Manolakis; Andreas N Kapsoritakis; Elisavet K Tiaka; Spyros P Potamianos
Journal:  Dig Dis Sci       Date:  2011-01-04       Impact factor: 3.199

8.  Update on the pathogenesis and management of pouchitis.

Authors:  Saleem Chowdhry; Jeffry A Katz
Journal:  Curr Infect Dis Rep       Date:  2014-12       Impact factor: 3.725

Review 9.  Fecal calprotectin use in inflammatory bowel disease and beyond: A mini-review.

Authors:  Bashaar Alibrahim; Mohammed I Aljasser; Baljinder Salh
Journal:  Can J Gastroenterol Hepatol       Date:  2015-04

10.  Consecutive Monitoring of Fecal Calprotectin and Lactoferrin for the Early Diagnosis and Prediction of Pouchitis after Restorative Proctocolectomy for Ulcerative Colitis.

Authors:  Takayuki Yamamoto; Takahiro Shimoyama; Takuya Bamba; Koichi Matsumoto
Journal:  Am J Gastroenterol       Date:  2015-04-28       Impact factor: 10.864

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.